FAQ’ s
 |
FAQ' sWhat is CureXcell™?
Why CureXcell™? How can I receive CureXcell™ for my patients? What are the indications for use? What is the safety profile? What is the clinical efficacy? What is the method of administration? What is CureXcell™? CureXcell™ is a mixture of white blood cells including monocytes/macrophages, neutrophils; lymphocytes obtained from young (18-40 yrs old) healthy donor blood which is put in a more active state (activation). CureXcell™ replenishes the imbalanced inflammatory environment in the non-healing wound with functionally-active immune cells which release the necessary growth factors important for healing. This recreates the environment for natural wound healing and debridement. Why CureXcell™? CureXcell™ is an advanced cell based therapy for the treatment of hard-to-heal wounds. The wound healing process is a complex perfectly orchestrated process that can only be established by the continuous communication between the active immune cells. Only CureXcell™ can replenish the wound bed with healthy young activated white blood cells to re-establish the natural wound healing environment . CureXcell™ enhances the wound healing capability of the patient despite his/her compromised state of the immune cells. How can I receive CureXcell™ for my patients? CureXcell™ is currently available for sale in Israel only. The company is currently working towards obtaining market approval in North America and Europe. What are the indications for use? This product has been approved in Israel for the treatment of chronic wounds. It has been used in Israel for a variety of wound types such as pressure ulcers, diabetic foot ulcers, and post-operative wounds (deep sternal wound infection, post cesarean operation, post orthopedic surgery, and post abdominal surgeries). What is the safety profile? More than 5,000 patients with various wounds have been treated with CureXcell™ with an excellent safety profile. What is the clinical efficacy? In a non-randomized controlled Phase IV trial comparing CureXcell™ to standard of care for chronic, severe full thickness (stage III/IV) hard to heal ulcers, there was a five-fold increase in the percentage of complete closure of the wounds vs. standard of care (N=38, p<0.001). In another study, the effect of CureXcell™ treatment was studied in deep sternal wound infections (DSWI) prospectively and compared to a four year historical control standard of care cohort. Mortality was 3% (2/66) in the CureXcell™ group vs 29.7% (19/64) in the control group. No side effects related to the treatment were reported. What is the method of administration? The suspension should be injected superficially throughout the wound using a 25 gauge needle.
|
© All rights reserved to MacroCure CureXcell™ is currently available for sale in Israel only |
 |